Ocular Therapeutix (NSDQ:OCUL) yesterday said it dosed the first patients in a Phase 3 clinical trial of its Dextenza drug-device combination.
The U.S.-based Phase 3 clinical trial is a multi-center, 1:1 randomized, double-masked, placebo-controlled trial slated to enroll 80 patients. The study will evaluate Dextenza 0.4mg to treat allergic conjunctivitis and ocular itching versus a placebo vehicle puncture plug using Ophthalmic Research Associates’s modified Conjunctival Allergen Challenge Model, according to the company.
Get the full story on our sister site, Drug Delivery Business.